General Information of Drug (ID: DME78MS)

Drug Name
O2-Sulfo-Glucuronic Acid Drug Info
Synonyms IDS
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
46936333
TTD Drug ID
DME78MS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CVBT-141H DMYPXQ2 Coronary artery disease BA80 Phase 2 [2]
Riferminogene pecaplasmid DMBKN4P Critical limb ischemia BD4Y Discontinued in Phase 3 [3]
Formic Acid DMNFZC6 Discovery agent N.A. Investigative [1]
N,O6-Disulfo-Glucosamine DMYCV7U Discovery agent N.A. Investigative [1]
Naphthalene Trisulfonate DML6FI3 Discovery agent N.A. Investigative [1]
5-AMINO-NAPHTALENE-2-MONOSULFONATE DMYTUNE Discovery agent N.A. Investigative [4]
Sucrose Octasulfate DMET64R Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 7 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
VM-202 DMSW80U Angina pectoris BA40 Phase 3 [5]
Donaperminogene seltoplasmid DMH8IT5 Diabetic foot ulcer BD54 Phase 3 [6]
ANG-3777 DMGP8WX Delayed graft function 4B24.0 Phase 3 [7]
Ficlatuzumab DMG65WH Multiple myeloma 2A83 Phase 2 [8]
Collategene DM27H0P Peripheral Ischemic Ulcers BD41 Phase 2 [9]
MP0250 DMR3VCY Non-small-cell lung cancer 2C25.Y Phase 1/2 [8]
ABI-011 DM1KD7U Lymphoma 2A80-2A86 Phase 1 [8]
TAK-701 DML3M0O Advanced malignancy 2A00-2F9Z Phase 1 [10]
Rilotumumab DMD8ZSW Grade IV malignant glioma 2A00.0 Discontinued in Phase 2 [11]
N,O6-Disulfo-Glucosamine DMYCV7U Discovery agent N.A. Investigative [1]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heparin-binding growth factor 1 (FGF1) TTMY81X FGF1_HUMAN Inhibitor [1]
Hepatocyte growth factor (HGF) TT4V2JM HGF_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Clinical pipeline report, company report or official report of CVBT.
3 Riferminogene pecaplasmide. Am J Cardiovasc Drugs. 2010;10(5):343-6.
4 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
5 Therapeutic angiogenesis using naked DNA expressing two isoforms of the hepatocyte growth factor in a porcine acute myocardial infarction model. Eur J Cardiothorac Surg. 2008 Oct;34(4):857-63.
6 Clinical pipeline report, company report or official report of ViroMed.
7 Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury. Kidney Int Rep. 2020 Sep 25;5(12):2325-2332.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010 Sep;17(9):1152-61.
10 Targeting MET in cancer: rationale and progress.Nat Rev Cancer.2012 Jan 24;12(2):89-103.
11 Clinical pipeline report, company report or official report of Amgen (2009).